Best Life Sciences Companies in Montana, United States
The 33 best Life Sciences companies in Montana, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: LigoCyte Pharmaceuticals.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Montana
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LigoCyte Pharmaceuticals Vaccines for infectious diseases such as influenza, noroviral infections. | $60M | 172 mo ago | Acquired | 40 | Donald Beeman CEO | — | — | — |
| 2 | Microbion Developing novel anti-infectives to combat biofilm-related and antibiotic-resistant infections | $39M | 69 mo ago | Series A | 15 | — | ZURB FoundationAmazon Web ServicesNginx+14 | 131 patents Bismuth-thiol antimicrobial and anti‑inflammatory agents for medical and industrial applications | — |
| 3 | Inimmune Developing immunotherapies and vaccine adjuvants to improve human health | $22M | 75 mo ago | Series A | 35 35 → 36 (+3%) | Kendal Ryter VP Product Development | WordPressMySQLPHP+23 | 38 patents Innate immune activation using STING and TLR agonist small molecules and phage‑targeting therapeutics | — |
| 4 | Montana Molecular Fluorescent biosensors and probes | $9M | 18 mo ago | Funding Raised | — | Anne Marie Quinn Founder | Cart FunctionalityWooCommerceWordPress+29 | 31 patents Patents concentrated in computing, sensing & instrumentation | — |
| 5 | Promiliad Biopharma Drug discovery company focussed on novel natural product-like small molecules in combinatorial arrays for… | $9M | 21 mo ago | Funding Raised | 6 | Priestley Nigel Founder | — | — | — |
| 6 | FYR Diagnostics Provider of in-vitro diagnostic tests for the detection of diseases | $8M | 27 mo ago | Series A | 14 | — | — | — | — |
| 7 | RestorEar Developer of cold therapy device for hearing loss prevention | $8M | 18 mo ago | Funding Raised | — | Curtis King Co-Founder & CEO | — | 4 patents Localized hypothermic therapy devices for ear cooling and treatment | — |
| 8 | Swan Valley Medical Provider of urological surgical instruments | $7M | 12 mo ago | Series A | 6 | Ronald Zook President & CEO | — | — | — |
| 9 | Golden Helix Genomic data analysis software solutions for precision medicine and clinical labs | $4M | 37 mo ago | Funding Raised | 22 22 → 23 (+5%) | — | DreamWeaverBootstrapVue.js+8 | — | — |
| 10 | NanoValent Developing targeted nanosphere therapeutics for improved cancer treatment and other diseases | $4M | 38 mo ago | Funding Raised | 4 | — | — | — | — |
| 11 | MitoSense Developer of treatments for neurodegenerative diseases | $4M | 33 mo ago | Seed | — | Robert Elliott Founder | — | — | — |
| 12 | Zero Online platform offering nutrition and fitness programs based on health assessment | $3M | 77 mo ago | Series A | 19 | Tom Conrad CEO | WebflowGoogle CloudNginx+18 | 35 patents AI-driven intent/comprehension engine, advanced water filtration, and air‑lock elimination technologies. | — |
| 13 | Magnesim Development Company Metal Alloy Technology used for Orthopedic Sports Medicine- knee, shoulder, foot & ankle repair | $2M | 91 mo ago | Seed | 2 | — | — | — | — |
| 14 | RMBIO Producer of high-performance cell culture media supplements, sera, and protein fractions | $2M | 136 mo ago | Series A | 10 | — | Cart FunctionalityShopifyShop Pay+20 | — | — |
| 15 | Truwl Provider of online data analysis tool and platform for scientific study and research purposes | $2M | 70 mo ago | Seed | 3 | — | — | — | — |
| 16 | PurCell Bio Developer of cell culture media for research purpose | $841K | 50 mo ago | Seed | 2 | Elizabeth Corbin Founder & CEO | — | — | — |
Top 12 Life Sciences companies in Montana
#1
Series A · Bigfork, Montana · founded 2006 · 6 employees$6.8Mraised▾
Provider of urological surgical instruments. The company focused on development and commercialization of urological surgical instruments incorporating new approaches and technologies to enhance and improve upon existing surgical devices and procedures. Its products comprise T-SPeC, a disposable instrument for suprapubic bladder catheterization; and LithoPro, a single-use instrument that creates unobstructed 40 Fr. suprapubic access to the bladder for the removal of bladder calculi (cystolithotripsy), as well as to provide drainage and removal of tissue fragments during procedures for benign prostatic hyperplasia.
- Oct 2025Series A$100K
- Jul 2024Series A$40K
- May 2023Series A$100K
- Apr 2022Series A$40K
#2
Funding Raised · Bozeman, Montana · founded 2007$9.3Mraised▾
Montana Molecular develops fluorescent biosensors and probes for use in cell-based assays. Its sensors are available with both red and green fluorescence, and include cADDis, DAG, PIP2, R-GECO and ArcLight Voltage sensors. Based on these sensors, the company provides cADDis-cAMP assays for the detection of cyclic adenosine monophosphate in living cells, DAG assays, PIP2 assays, R-GECO assays that can simultaneously detect both cAMP and Ca ions, ans ArcLight Voltage assays to study the electrical activity of live neurons. In addition, Montana Molecular provides services for custom assay development, BacMam production and production of stable cell lines.
- Apr 2025Grant (prize money)$600K
- May 2022Grant (prize money)$600K
- Sep 2019Grant (prize money)$1M
- Sep 2018Grant (prize money)$250.8K
#3
Funding Raised · Bozeman, Montana · founded 2017$7.7Mraised▾
Developer of cold therapy device for hearing loss prevention. The company specializes in hearing health, particularly with products designed to protect and potentially restore hearing after noise exposure such as their ReBound and ReBoundLite devices, which use cold therapy to help mitigate noise-induced hearing damage.
- Apr 2025Grant (prize money)$1.9M
- Mar 2025Grant (prize money)$2.5M
- May 2024Grant (prize money)$970.5K
- Apr 2021Grant (prize money)$2.2M
#4
Funding Raised · Missoula, Montana · founded 2002 · 6 employees$8.5Mraised▾
Promiliad Biopharma is a drug discovery company focussed on novel natural product-like small molecules in combinatorial arrays. The company has developed a proprietary drug discovery process ReBACS (Recombinant Biotechnology Assisted Combinatorial Synthesis). Its drug discovery programs are targeted against pathogenic organisms including Gram-negative bacteria, antifungal agents, and the protozoal pathogen Cryptosporidium that causes diarrheal disease in humans. The company specializes in the production of natural products and their derivatives, both as bulk quantities of pure compounds and as arrayed libraries of compounds suitable for high throughput screening.
- Jan 2025Grant (prize money)$751.1K
- Sep 2018Grant (prize money)$1M
- Jul 2016Grant (prize money)$1.7M
- Jul 2014Grant (prize money)$287.8K
#5
Series A · Missoula, Montana · founded 2016 · 14 employees$8Mraised▾
Provider of in-vitro diagnostic tests for the detection of diseases. The company develops a portfolio of biomarker detection technologies with a focus on nucleic acid amplification that enables the accelerated prediction, diagnosis, and management of human and agricultural diseases.
- Aug 2024Series A$8M
- Aug 2021Grant (prize money)$351.1K
- Dec 2020Grant (prize money)$256K
- Sep 2019Grant (prize money)$303K
#6
Series A · Bozeman, Montana · founded 2000 · 15 employees$38.8Mraised▾
Developing novel anti-infectives to combat biofilm-related and antibiotic-resistant infections. This clinical-stage pharmaceutical company is focused on creating a new class of compounds to treat difficult-to-treat infections. They are dedicated to developing novel medicines that address unmet medical needs, providing physicians with options to improve patient outcomes. Their lead therapeutic candidate has broad-spectrum activity and a novel mechanism of action that halts microbial cellular metabolism, preventing and eradicating biofilms. They employ a site-specific delivery approach to maximize efficacy and minimize off-target effects, potentially reducing the risk of antibiotic resistance. They are actively seeking collaborations to explore the therapeutic potential of their technology in treating serious infectious diseases globally. Their pipeline includes programs for diabetic foot ulcer infection, orthopedic device-related infection, and respiratory infection. They are supported by funding from institutions and are committed to helping patients through innovative solutions for serious, resistant infections.
- Jan 2021Series A$4.1M
- Jan 2017Series A$25.4M
- Jan 2016Series A$5.9M
- Apr 2013Series A$1.2M
#7
Seed · Great Falls, Montana · founded 2019$3.8Mraised▾
Developer of treatments for neurodegenerative diseases. The company uses a proprietary Mitochondria Organelle Transplantation (MOT) technology to replenish mitochondria to treat neurodegenerative disorders such as ALS, Alzheimers, and Parkinson's.
- Jan 2024Seed$3.7M
- Aug 2022Seed$250K
- Feb 2020Seed$340K
#8
Acquired · Bozeman, Montana · founded 1998 · 40 employees$59.7Mraised▾
LigoCyte focused on developing novel vaccines for infectious diseases. Its lead programs are vaccines against influenza and norovirus. It has developed technologies used in a wide range of virus-like particle (VLPs) vaccines. The human immune system recognizes VLPs as a live virus and defends by generating an immune response. It has funded its product development through a mix of private investment as well as grants and contracts administered through the NIH and the U.S. Department of Defense. As on Oct 2012, Ligocyte is acquired by Takeda Pharmaceuticals.
- Jun 2012Series C$2M
- Jun 2011Series C$5.5M
- May 2010Series C$6.6M
- Aug 2009Series C$29.5M
#9
Funding Raised · Bozeman, Montana · founded 1998 · 22 employees$3.9Mraised▾
Genomic data analysis software solutions for precision medicine and clinical labs. They provide scalable next-generation sequencing (NGS) analysis software, enabling clinical labs and research centers to streamline variant interpretation and reporting. Their integrated platform supports variant annotation, filtering, and secure data warehousing. They offer solutions for cancer, germline, and pharmacogenomics analysis, adhering to ACMG and AMP guidelines. Their software empowers users with automated workflows, cloud-based deployment options, and comprehensive support. They focus on delivering user-centric solutions for complex genomic workflows, facilitating efficient and repeatable processes. They offer flexible pricing models and curated annotation databases, catering to labs of all sizes. Their solutions support hospitals, commercial testing labs, and pharmaceutical research, advancing precision medicine through innovative software.
- Sep 2023Grant (prize money)$399.8K
- Mar 2018Grant (prize money)$1.3M
- Mar 2018Grant (prize money)$156.2K
- Sep 2017Grant (prize money)$2M
#10
Funding Raised · Bozeman, Montana · founded 2006 · 4 employees$3.8Mraised▾
Developing targeted nanosphere therapeutics for improved cancer treatment and other diseases. The company focuses on a unique NANO-ADC like TARGETED NANOSPHERE (TNS) platform. This platform aims to significantly improve the delivery, safety, and performance of both existing and developing cancer therapeutics. The company collaborates with academic partners to advance its flexible platform technology. Their lead product is approaching clinical status. The company is seeking finance to further its development. The core management team possesses a proven track record of success, supported by a strong clinical and operational capability. This innovative approach holds promise for advancing the field of therapeutics.
- Aug 2023Grant (prize money)$1.4M
- Feb 2016Grant (prize money)$1.8M
- Oct 2013Grant (prize money)$510K
- Jun 2012Grant (prize money)$15K
#11
Series A · Missoula, Montana · founded 2016 · 35 employees$22Mraised▾
Developing immunotherapies and vaccine adjuvants to improve human health. It focuses on discovering and developing disease-modifying immunotherapies, including Toll-like receptor (TLR) agonists, for immuno-oncology and allergy. Their pipeline includes clinical-stage and pre-clinical programs centered around innate immune agonists and antagonists as next-generation vaccine adjuvants. It reate novel immunotherapeutics for cancer, allergy, autoimmunity, and vaccines, partnering with universities and biotech companies to co-create and develop innovative solutions. It leverages expertise in synthetic chemistry, immunology, and clinical translation to harness the immune system and make lasting clinical impacts.
- Jul 2020Series A$22M
- Jul 2020Grant (prize money)$2M
- Feb 2018Grant (prize money)$1.2M
#12
Series A · Billings, Montana · founded 2017 · 19 employees$2.8Mraised▾
Online platform offering nutrition and fitness programs based on health assessment. The platform offers a quiz for individuals to provide personalized guidance from experts and can track progress by using an app.
- May 2020Series A$8M
- Aug 2019Seed$2.8M
- Sep 2018Seed—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
What Montana researches in biotechnology
- Montana State University12
- University of Montana2
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.